US Government Accelerates Approval Path for Psychedelic Mental Health Therapies

President Donald Trump has signed an executive order directing the Food and Drug Administration (FDA) to expedite the review and approval process for psychedelic-based treatments targeting mental illnesses. The order specifically targets products with 'breakthrough therapy' status, which the FDA identifies as offering substantial improvement over existing options for serious conditions. Under the new directive, review windows for these therapies will be slashed from the previous six-to-ten-month timeframe to just one or two months. This regulatory shift is expected to alleviate a primary bottleneck for the industry, as the perceived risk of the regulatory environment has historically deterred significant capital investment in psychedelic medicine. Beyond the timeline acceleration, the order mandates the Secretary of Health and Human Services to allocate $50 million to advance private sector research. Furthermore, the administration intends to expedite the reclassification of Schedule I substances, including ibogaine and psilocybin, which are currently categorized as having no accepted medical use. Market reaction was immediate and pronounced on Monday. Compass Pathways (CMPS) saw shares climb approximately 39%, while AtaiBeckley (ATAI) surged 32%. Definium Therapeutics (DFTX) also recorded a gain of over 4%. These firms are currently advancing clinical trials for conditions including treatment-resistant depression, social anxiety disorder, and PTSD.